Efficacy assessment of diverse antibiotic combinations in bismuth quadruple regimens and risk factors for Helicobacter pylori eradication: a retrospective single-center study in China

被引:0
|
作者
Li, Zhen [1 ]
Dong, Zhao-Jing [2 ]
Ding, Hai-Ou [3 ]
Gao, Hong-Jie [3 ]
Cheng, Jian-Ping [1 ]
机构
[1] Civil Aviat Gen Hosp, Dept Gastroenterol & Oncol, 76 Chaoyang Rd, Beijing 100123, Peoples R China
[2] Civil Aviat Gen Hosp, Dept Med Record, Beijing, Peoples R China
[3] Civil Aviat Gen Hosp, Dept Pharm, Beijing, Peoples R China
关键词
Helicobacter pylori; quadruple therapy; antibiotic combinations; bismuth; eradication rate; DUAL THERAPY; VONOPRAZAN; RABEPRAZOLE; OMEPRAZOLE; INFECTION; 1ST-LINE; SMOKING; TRIAL;
D O I
10.62347/SMLE6245
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: To evaluate the efficacy of various antibiotic combinations in bismuth quadruple therapy for H. pylori eradication. Methods: This study involved a retrospective analysis of data collected from a single medical center in Beijing, China. A cohort of patients was enrolled with H. pylori infection that underwent 14-d bismuth quadruple therapy (antibiotics, omeprazole, and bismuth) and received a test for cure between January 2020 and December 2023. Patient demographics and therapeutic regimens were meticulously compiled and subsequently categorized into five groups based on antibiotic combinations used: amoxicillin-clarithromycin, amoxicillin-levofloxacin, amoxicillin-doxycycline, clarithromycin-levofloxacin, and clarithromycin-doxycycline. The eradication rates were then calculated and compared across these distinct regimens. Results: This study evaluated a cohort of 575 patients, comprising 261 males and 314 females. A significant majority of patients, 76.3% (n=439), received a treatment regimen comprising amoxicillin and clarithromycin. The amoxicillin-levofloxacin combination was administered to 8.5% (n=49) of the patients. A smaller proportion, 1.7% (n=10), were treated with an amoxicillin-doxycycline regimen. Furthermore, 8.9% (n=51) of the patients received a clarithromycin-levofloxacin regimen, while 4.5% (n=26) were treated with a combination of clarithromycin and doxycycline. Patients treated with the amoxicillin-doxycycline-based regimen exhibited significantly higher eradication rates than other regimens (70.0% vs 65.4%, 32.7%, 54.9%, and 42.3%, respectively; P=0.001). Furthermore, the results indicated that risk factors such as smoking and alcohol consumption had a significant impact on the eradication rates (all P<0.01). Conclusion: This study reveals significant differences in the eradication rates of various antibiotic combinations for H. pylori infection. Of particular note is that the amoxicillin-doxycycline-based regimen outperformed other antibiotic combinations, with a considerably higher eradication rate. This provides vital insight to inform clinical decision-making in the treatment of H. pylori.
引用
收藏
页码:75 / 83
页数:9
相关论文
共 50 条
  • [31] Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study
    Qu, Peng
    Liu, Xiaoming
    Xia, Xiujuan
    Xie, Xiaoran
    Luo, Ju
    Cheng, Sha
    Chi, Jingshu
    Liu, Peng
    Li, Huan
    Zhao, Wenfang
    Yang, Huihao
    Xu, Canxia
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [32] Analysis of Risk Factors for Cholelithiasis: A Single-Center Retrospective Study
    Baddam, Anusha
    Akuma, Ogbonnaya
    Raj, Rohan
    Akuma, Chinaza M.
    Augustine, Sana W.
    Hanafi, Ihab Sheikh
    Singh, Gauravdeep
    Zain, Ahmer
    Azizz, Nasihudeen
    Singh, Manjeet
    Makheja, Kainat
    Rahul, F. N. U.
    Khan, Aadil
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [33] Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study
    Cheng, Sha
    Li, Huan
    Luo, Ju
    Chi, Jingshu
    Zhao, Wenfang
    Lin, Jiahui
    Xu, Canxia
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [34] Efficacy and safety of Qingwei Zhitong pellets (清胃止痛微丸)-containing quadruple therapy for Helicobacter pylori eradication:a prospective,single-center,randomized trial
    CHENG Jianping
    FAN Chanjuan
    ZHAI Lili
    WANG Hui
    XIE Dongling
    CAI Yong
    LI Zhen
    HUANG Kun
    BAI Qixuan
    Journal of Traditional Chinese Medicine, 2025, 45 (02) : 430 - 436
  • [35] ERADICATION RATE AND SAFETY OF REDUCED-TETRACYCLINE VS STANDARD-TETRACYCLINE, FURAZOLIDONE-CONTAINING QUADRUPLE REGIMEN FOR HELICOBACTER PYLORI INFECTION: A SINGLE CENTER RETROSPECTIVE STUDY IN CHINA
    Sun, Yingchao
    Zhu, Mengjia
    Yue, Lei
    Zhao, Yiru
    Hu, Weiling
    GASTROENTEROLOGY, 2023, 164 (06) : S379 - S379
  • [36] The efficacy of Modified bismuth quadruple therapy for Helicobacter pylori infection in Korea. A single arm prospective observational study
    Choe, J.
    Jung, S.
    Kim, S.
    Hyun, J.
    Jung, Y.
    Koo, J.
    Yim, H.
    Lee, S.
    HELICOBACTER, 2019, 24
  • [37] Independent risk factors predicting eradication failure of standard bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection in Taiwan
    Shie, Chang-Bih
    Tsay, Feng-Woei
    Wu, Deng-Chyang
    Kao, Sung-Shuo
    Chen, Yan-Hua
    Tsai, Kun-Feng
    Huang, Wen-Wei
    Tang, Sheng-Yeh
    Kuo, Li-Fu
    Wu, I-Ting
    Hsu, Ping-, I
    ADVANCES IN DIGESTIVE MEDICINE, 2025, 12 (01)
  • [38] Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial
    Shao, Qiao-Qiao
    Yu, Xue-Chun
    Yu, Miao
    Ma, Jing
    Zhao, Jun-Bo
    Yuan, Lin
    Qi, Ya-Bin
    Hu, Ruo-Bing
    Wei, Pei-Ru
    Xiao, Wei
    Lan, Ling
    Jia, Bai-Ling
    Zhang, Lian-Zhong
    Ding, Song-Ze
    HELICOBACTER, 2022, 27 (02)
  • [39] The Efficacy of Two-Week Quadruple First-Line Therapy with Bismuth, Lansoprazole, Amoxicillin, Clarithromycin on Helicobacter pylori Eradication: A Prospective Study
    Ergul, Bilal
    Dogan, Zeynal
    Sarikaya, Murat
    Filik, Levent
    HELICOBACTER, 2013, 18 (06) : 454 - 458
  • [40] EFFICACY AND TOLERABILITY OF BISMUTH-BASED ERADICATION THERAPY WITHOUT PPIS FOR HELICOBACTER PYLORI INFECTION IN PATIENTS WITH CORPUS ATROPHIC GASTRITIS: A RETROSPECTIVE SINGLE- CENTER EXPERIENCE
    Dilaghi, E.
    Luciano, C. M.
    Toniatti, M.
    Dottori, L.
    Ligato, I.
    Pivetta, G.
    Scalamonti, S.
    Esposito, G.
    Annibale, B.
    Lahner, E.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S175 - S175